NAD+: The Cell's Ledger for Energy and Repair

The short version

NAD+ (nicotinamide adenine dinucleotide) is a molecule every living cell needs to convert food into usable energy and to power the enzymes that repair damaged DNA. It is not a peptide — it is a coenzyme, a helper molecule that other enzymes depend on — but it sits at the center of aging research because tissue NAD+ levels reliably decline as people get older.

Because raising blood NAD+ is easier to test than raising it inside specific tissues, most human trials use oral precursors — nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) — rather than NAD+ itself, which cells do not absorb well intact. Multiple randomized, placebo-controlled trials have shown these precursors reliably and dose-dependently raise blood NAD+ with a good short-term safety record ^[2][5]. What is far less settled is whether that increase translates into a measurable clinical benefit — a 2025 review of the human evidence concluded the data are still limited and tissue-specific NAD+ dynamics remain sparsely studied ^[1].

This page summarizes what the trials actually measured. It does not recommend a dose, a product, or a use for any person.

What it is

NAD+ is built from two nucleotides — a nicotinamide mononucleotide and an adenosine monophosphate — joined by a pair of bridging phosphate groups, with a pyridine nicotinamide ring at one end and an adenine ring at the other. Its molecular formula is C21H27N7O14P2. It exists in the body in an oxidized form (NAD+) and a reduced form (NADH), and the ratio between the two is a working readout of a cell's metabolic state.

In the research and supplement marketplace, NAD+ appears in three main forms: as the free coenzyme itself (poorly absorbed orally), as oral precursors that the body converts into NAD+ — chiefly NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) — and as compounded IV or injectable formulations marketed by wellness clinics. These three forms have meaningfully different evidence bases, which this page keeps separated rather than treating 'NAD+' as one interchangeable product.

How it works

NAD+ does two distinct jobs in a cell. First, as a redox carrier, it shuttles electrons through glycolysis, the TCA cycle, and oxidative phosphorylation — the core metabolic pathway that turns glucose and fat into ATP. Second, as a consumed signaling substrate, it is used up (not just passed along) by a set of enzymes that depend on it to function: the sirtuins (SIRT1 through SIRT7), which regulate gene expression and DNA repair through deacetylation; PARP1, the DNA-damage-response enzyme; and CD38, an NAD-consuming ectoenzyme that rises with age and inflammation and is a leading candidate explanation for why tissue NAD+ falls over time ^[4][6].

The rate-limiting enzyme in NAD+'s own recycling pathway is NAMPT (nicotinamide phosphoribosyltransferase), which regenerates NAD+ from nicotinamide, the byproduct left over after sirtuins and PARPs consume it. The logic behind precursor supplementation is straightforward: if CD38 is burning through the NAD+ pool faster than NAMPT can replace it, feeding the salvage pathway more raw material (via NMN or NR) should raise the pool back up — and trial data confirm that it does, at least in blood ^[2][5]. Whether that also restores NAD+ inside the specific tissues where sirtuins and PARPs are working is a separate, less-answered question ^[1].

What the research shows

The current authoritative synthesis. A 2025 narrative review of the human clinical evidence on NAD+ precursor supplementation in aging concluded that human trials have so far shown limited efficacy, that age-related NAD+ decline has been consistently observed only in a limited number of human studies, and that tissue-specific NAD+ dynamics remain sparsely characterized — the review calls for more clinical study of systemic and tissue-specific NAD+ metabolism rather than continued extrapolation from rodent data ^[1].

NMN, dose-ranging RCT. In a multicenter, double-blind, placebo-controlled trial, oral NMN at 300–900 mg/day for 60 days dose-dependently raised blood NAD+ in middle-aged adults, with 600 mg/day identified as the optimal dose tested. Walking distance and quality-of-life scores improved versus placebo, a biological-age marker did not increase, and no safety issues were reported at any dose ^[2].

NMN and insulin sensitivity. In a smaller trial, 10 weeks of oral NMN at 250 mg/day improved muscle insulin sensitivity — measured by hyperinsulinemic-euglycemic clamp, a gold-standard method — in prediabetic, postmenopausal women, though body composition and HbA1c were unchanged ^[3].

NR, dose-ranging safety trial. Across 8 weeks, oral NR at 100–1000 mg/day dose-dependently raised whole-blood NAD+ by 22%, 51%, and 142% respectively in healthy overweight adults, with no flushing and no significant difference in adverse events from placebo at any dose. NR did not raise LDL cholesterol or disrupt one-carbon metabolism ^[5].

Why NAD+ falls with age. Animal work identifies CD38 as the principal NAD-consuming enzyme whose activity rises with age; CD38-knockout mice are protected against age-related NAD+ decline, with preserved SIRT3 activity and better mitochondrial function ^[6]. A broader review situates this within the full network of NAD-consuming enzymes across yeast, worm, mouse and human studies ^[4].

A newer, more targeted result. A 2025 study in human myocardium and a mouse model of heart failure with preserved ejection fraction (HFpEF) found that oxidized NAD+ repletion restored a ketogenic enzyme (HMGCS2) via deacetylation, increased fatty-acid oxidation, and rescued cardiac function — an effect that disappeared when the enzyme was knocked out, tying the benefit specifically to that mechanism rather than to NAD+ in general ^[7].

Reported effects, cautions & safety

The signed corpus behind this site carries no community-sourced anecdotal reports for NAD+ specifically, so this section sticks to the cited cautions the literature itself raises, rather than inventing an anecdotal layer that was not in the source research.

• Oral bioavailability is a real bottleneck. NAD+ itself is poorly taken up by cells intact; most researchers treat precursors (NMN, NR) as the rational oral route, and some argue plain oral 'NAD+' capsules are largely ineffective as delivered.
• Blood NAD+ is not the same as a clinical outcome. Raising blood NAD+ is well demonstrated across multiple RCTs, but translation to hard endpoints — longevity, disease prevention — in humans remains unproven; the 2025 review is explicit that human efficacy data are still limited and tissue-level data are sparse ^[1].
• Much of the strongest anti-aging data is rodent-only and may not extrapolate to humans.
• IV/injectable NAD+ therapy rests on a thin evidence base relative to how aggressively it is marketed. Infused NAD+ is cleared from plasma quickly, and infusions run too fast have been associated with chest or abdominal discomfort, flushing and nausea.
• Compounded injectable NAD+ carries contamination risk. A compounded NAD+ injection was subject to an FDA Class I recall for elevated bacterial endotoxin — the most serious class of recall the agency issues.
• A theoretical cancer-metabolism concern exists. Because NAD+ supports proliferating cells generally, boosting it could in principle help fuel an existing cancer's metabolism; NAD+'s role in oncology is described in the literature as dual and context-dependent, which argues for caution in cancer populations specifically.
• NMN's regulatory status is contested. The FDA has taken the position that NMN is excluded from the dietary-supplement definition because it was investigated as a drug first, creating marketplace uncertainty for that specific precursor.
• Supplement-grade product quality varies widely, and third-party testing is not guaranteed across the market.

Where it fits in the new age of longevity

NAD+ is the lead compound on this desk because it has the deepest and most direct human trial evidence of the three, even though that evidence stops short of proving a clinical benefit. Where MOTS-c offers a mitochondrial-signaling story still mostly confined to animal studies, and Epitalon offers a pineal/telomerase story built on a narrower research base, NAD+ sits in the middle: solid pharmacokinetic and safety data in humans, genuinely open questions about whether raising it changes anything that matters. See the comparison page for how the three stack up.